The content below is part of a paid sponsorship and is not an endorsement by the American Association for Cancer Research^® (AACR), nor does it reflect the views or opinions of the AACR or its members.

Bridging Emerging Immunotherapy Data to Clinical Practice in Solid Tumors

The role of immunotherapy in the treatment of solid tumors continues to expand as new therapeutic targets, mechanisms of action, and combination strategies emerge. As clinical trial data rapidly evolves, oncology clinicians must continuously evaluate how these developments translate into meaningful treatment decisions for patients in real-world practice.

Emerging Frontiers in Immunotherapy: Bridging Data and Practice in Solid Tumors is a 90-minute hybrid symposium designed to help clinicians interpret the latest scientific advances and apply them within modern oncology care.

Join expert faculty on Saturday, April 18, 2026, from 7:00 pm – 8:30 pm PT at the Hilton San Diego Bayfront for an engaging discussion focused on novel immunotherapy targets and their implications for clinical practice. Through expert-led presentations and discussion, faculty will review key clinical trial findings, examine the scientific rationale behind emerging therapies, and explore actionable strategies for integrating new evidence into patient care.

The program will highlight areas where immunotherapy innovation is rapidly evolving, including melanoma, non–small cell lung cancer (NSCLC), and other solid tumors. Faculty will discuss how emerging targets and treatment approaches may influence current therapeutic paradigms and provide practical guidance for incorporating new data into everyday oncology practice.

This educational activity is sponsored by Medscape Education and supported by a grant from Regeneron Pharmaceuticals, Inc. This is not an official program of the American Association for Cancer Research Annual Meeting.

---